Emerging targets in cancer drug resistance

Shashank Kumar; Prem Prakash Kushwaha; Sanjay Gupta

doi:10.20517/cdr.2018.27

Emerging targets in cancer drug resistance

Cancer Drug Resist. 2019 Jun 19;2(2):161-177. doi: 10.20517/cdr.2018.27. eCollection 2019.

Authors

Shashank Kumar¹, Prem Prakash Kushwaha¹, Sanjay Gupta^{2

3

4

5

6}

Affiliations

¹ School of Basic and Applied Sciences, Department of Biochemistry and Microbial Sciences, Central University of Punjab, Bathinda 151001, India.
² Department of Urology, Case Western Reserve University, Cleveland, Ohio 44106, USA.
³ The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio 44106, USA.
⁴ Department of Nutrition, Case Western Reserve University, Cleveland, Ohio 44106, USA.
⁵ Divison of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, Ohio 44106, USA.
⁶ Department of Urology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio 44106, USA.

Abstract

Drug resistance is a complex phenomenon that frequently develops as a failure to chemotherapy during cancer treatment. Malignant cells increasingly generate resistance to various chemotherapeutic drugs through distinct mechanisms and pathways. Understanding the molecular mechanisms involved in drug resistance remains an important area of research for identification of precise targets and drug discovery to improve therapeutic outcomes. This review highlights the role of some recent emerging targets and pathways which play critical role in driving drug resistance.

Keywords: Drug resistance; FOXO transcription factors; Keap1-Nrf2; MIEN1; PI3K-Akt; annexins; focal adhesion kinases; gene splicing; microRNA; sphingolipids; transforming growth factor-β.

Publication types

Review